Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
P. Kokkoris, F.X. Pi-Sunyer.
Obesity and endocrine disease.
Endocrinol Metab Clin North Am, 32 (2003), pp. 895-914
[2.]
M. Maccario, S. Grottoli, M. Procopio, S.E. Oleandri, A. Barberis, E. Ciccarelli, et al.
Effect of bromocriptine on insulin, growth hormone and prolactin responses to arginine in obesity.
J Endocrinol Invest, 19 (1996), pp. 219-223
[3.]
A. Cincotta, A. Meier.
Bromocriptine (Ergoset) reduces body weight and improves glucose tolerance in obese subjects.
Diabetes Care, 19 (1996), pp. 667-670
[4.]
M. Doknic, S. Pekic, M. Zarkovic, M. Medic-Stojanoska, C. Dieguez, F. Casanueva, et al.
Dopaminergic tone and obesity: an insight from prolactinomas treated with bromocriptine.
Eur J Endocrinol, 147 (2002), pp. 77-84
[5.]
Y. Greenman, K. Tordjman, N. Stern.
Increased body weight associated with prolactin secreting pituitary adenomas: weight loss with normalization of prolactin levels.
Clin Endocrinol (Oxf), 48 (1998), pp. 547-553
[6.]
E. Delgrange, J. Donckier, D. Maiter.
Letters to the editors.
Clin Endocrinol (Oxf), 50 (1999), pp. 271-272
[7.]
R. Yermus, S. Ezzat.
Does normalization of prolactin levels result in weight loss patients with prolactin secreting pituitary adenomas?.
Clin Endocrinol (Oxf), 56 (2002), pp. 561-562
Copyright © 2005. Sociedad Española de Endocrinología y Nutrición
